World Orphan Drug Alliance (WODA)

Medis forms an alliance WODA (World Orphan Drug Alliance) with the company Orpharm for the territory of Russia and CIS (Commonwealth of Independent States), with the company Vector Pharma for the territory of Middle East and Turkey, with the company OrphanDC for the territory of Latin America and with the company EffRx for Switzerland. 

The aim of this alliance is to provide the best service and flexibility to our pharmaceutical partners with orphan portfolios in a broader territory.

Vector Pharma is a full-service distributor in the region of Middle East, North Africa and Turkey with a focus on rare diseases - including gene and cell therapy - and oncology. It was founded in 2019 with a mission to help partners create access to their transformative medicines and technologies. The company was founded by a group of industry veterans and former government employees.

Orpharm is a full-service distribution company specializing in the rare disease and oncology segments of the Russian and the CIS pharmaceutical markets. The company's goal is to provide all the services needed for the products to reach the patients in need, instead of the local branch of a partner.

OrphanDC acts as a partner for Biotech companies in Latin America connecting Rare Diseases and Orphan Drugs. Their local and global capabilities and expertise focus on supporting their clients from the clinical development stage throughout the product lifecycle.

EffRx Pharmaceuticals is a Swiss commercial-stage pharmaceutical company focused on the late-stage development and commercialization of prescription medications for niche and orphan indications. The business model is centered around providing superior clinical and commercial value propositions for physicians, payers and patients.